Research Article

STAT4, *TRAF3IP2*, *IL10*, and *HCP5* Polymorphisms in Sjögren's Syndrome: Association with Disease Susceptibility and Clinical Aspects

Serena Colafrancesco,[1] **Cinzia Ciccacci** ⓘ**,**[2,3] **Roberta Priori,**[1] **Andrea Latini,**[2]
Giovanna Picarelli,[1] **Francesca Arienzo,**[1] **Giuseppe Novelli,**[2] **Guido Valesini,**[1]
Carlo Perricone ⓘ**,**[1] **and Paola Borgiani**[2]

[1]*UOC Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Italy*
[2]*Department of Biomedicine and Prevention, Genetics Section, University of Rome Tor Vergata, Italy*
[3]*UniCamillus, International University of Health and Medical Science, Rome, Italy*

Correspondence should be addressed to Cinzia Ciccacci; cinziaciccacci@libero.it

Sjögren's syndrome (SS) is a chronic autoimmune condition characterized by autoantibody production, sicca syndrome, and periepithelial lymphocytic lesions in target tissues. A predisposing genetic background is likely, and, to date, several polymorphisms in non-HLA genes have been explored with interesting results. We investigated the association between the *STAT4*, *TRAF3IP2*, *HCP5*, and *IL10* polymorphisms and SS susceptibility and their possible role in the modulation of clinical and laboratory features. 195 consecutive patients with SS were enrolled and clinical and laboratory data were collected. 248 age- and sex-matched healthy subjects were used as controls. Genotyping was performed by allelic discrimination assays. A case-control association study and a phenotype-genotype correlation analysis were performed. A genetic risk profile was developed considering the risk alleles. Both the variant alleles of rs7574865 in the *STAT4* gene and rs3099844 in the *HCP5* gene were significantly more prevalent in patients than in controls (OR = 1.91 and OR = 2.44, respectively). The variant allele of rs3024505 of *IL10* resulted to be a susceptibility allele (OR = 1.52), while the variant allele of rs1800872 seemed to confer a protective effect for the development of the disease (OR = 0.65). A risk genetic profile showed a higher probability to develop the disease in subjects with at least three risk alleles; subjects with 4 risk alleles were not observed in the controls. *HCP5* rs3099844 was associated with anti-SSA ($P = 0.006$, OR = 3.07) and anti-SSB ($P = 0.005$, OR = 2.66) antibodies, severity of focus score ($P = 0.03$, OR = 12), and lymphoma development ($P = 0.002$, OR = 7.23). Patients carrying the *STAT4* rs7574965 variant allele had a higher risk of monoclonal component and leukopenia ($P = 0.002$, OR = 7.6; $P = 0.048$, OR = 2.01, respectively). We confirmed the association of SS with the *STAT4* and *IL10* genes and we describe a novel association with *HCP5*. In particular, we describe an association of this specific SNP of *HCP5* not only with disease development but also with autoantibody production and focus score suggesting a potential contribution of this variant to a more severe phenotype.

1. Introduction

Sjögren's syndrome (SS) is a systemic autoimmune condition characterized by a chronic inflammatory reaction in the exocrine glands [1]. Periepithelial lymphocytic lesions are characteristically present in the SS salivary glands, and the "activated" epithelium is known to contribute to the development, maintenance, and progression of the local autoimmune responses [1].

The presence of a predisposing genetic background has been suggested, and different environmental agents act as triggers of the disease [1]. Indeed, latent viral infections harbouring salivary glands are causally implicated in epithelium activation [1], and the persistence of viral genetic material

seems to be able to alter epithelial cell biologic properties with consequent overexpression of type I IFN-inducible genes: the "*IFN signature*" [2]. The increased production of IFN provides protection from viral infections and drives the transcription of hundreds of genes implicated in antiviral response [3]. Moreover, IFN production in the SS salivary glands has been recently linked to endogenous retroviral element expression, normally silent [4]. Although in SS, a type I IFN signature has been proven both in the minor salivary glands (MSG) [5] and in peripheral blood cells [6]; a predominant type II IFN (IFNγ) production at tissue level compared to peripheral blood has been recently demonstrated [2, 7]. In the salivary glands, the main source of IFNγ is represented by CD4^{+}-infiltrating cells (Th1 cells) which are also in control for the production of other cytokines including IL-2 and IL-10 [8].

Compared to healthy subjects, higher serum levels of IL-10, also correlated with autoantibody production, have been detected in SS [9]. In addition, elevated levels of this cytokine seem to be present in patients' saliva with evidence of a positive correlation with disease activity [10]. However, the role of this cytokine in SS pathogenesis is still not clear. Given the evidence of an altered production of IL-10 in SS, polymorphisms in the *IL10* (interleukin 10) promoter have been investigated with controversial results [11–13].

To date, a broad spectrum of polymorphisms not related to *MHC* genes has been investigated in SS. Recently, Nezos and Mavragani classified three classes of genes whose polymorphisms are possibly implicated in disease pathogenesis: genes involved in the interferon (IFN) pathway, genes involved in B cell function, and genes involved in the NF-κB pathway [14].

Concerning the IFN pathway, a specific polymorphism (rs7574865) of *STAT4* (signal transducer and activator of transcription 4) seems to be associated with SS [15, 16] with evidence of a major risk in the homozygote variant [17]. Later on, other variants in the same gene appeared not only associated with SS but also with the increased expression of several IFN-inducible genes [17]. Genome-wide association studies (GWAS) confirmed the involvement of *STAT4* in SS predisposition [18–20].

The TRAF3-interacting protein 2 (*TRAF3IP2*) gene, also known as Act1, encodes for a protein known to be a negative regulator of B cell responses (by its interaction with CD40L and BAFF signalling) as well as a positive regulator of IL-17 signalling [21]. As these pathways are crucial in SS [22], polymorphisms of this gene might play a role in the disease susceptibility. Interestingly, mice deficient in Act1 develop systemic autoimmune disease with histological and serological features of human SS in association with systemic lupus erythematosus- (SLE-) like nephritis [23].

In our previous works, we described associations between SNPs in the *STAT4*, *IL10*, *TRAF3IP2*, and *HCP5* (HLA complex P5) genes and systemic lupus erythematosus (SLE) susceptibility [24–26]. Concerning *HCP5*, of note is the association that came out with the production of anti-Ro-SSA antibodies [25].

Taken all together, these considerations lead us to hypothesize a role of these polymorphisms in SS too.

For this purpose, we aimed to evaluate the association of polymorphisms in the *STAT4* (rs7574865), *TRAF3IP2* (rs33980500), *HCP5* (rs3099844), and *IL10* (rs1800872 and rs3024505) genes with SS susceptibility and to elucidate their role in the modulation of clinical and laboratory features in a cohort of Italian patients.

2. Materials and Methods

2.1. Sample Collection. One hundred ninety-five consecutive patients with SS (diagnosed according to the American-European Consensus Criteria) [27] were enrolled from our dedicated Sjögren's Clinic (Sapienza University of Rome). Study protocol included complete physical examination and blood drawing. The clinical and laboratory data were collected in a standardized, computerized, and electronically filled form including demographics, past medical history with date of diagnosis, comorbidities, and previous and concomitant treatments. The evaluation of clinical and laboratory parameters was assessed with a dichotomous score (present = 1; absent = 0). Written informed consent was obtained from each patient and the ethical committee of Sapienza University of Rome approved the study design. Two hundred forty-eight age- and ethnicity-matched healthy subjects, enrolled at the University of Rome Tor Vergata, served as controls. Demographic and clinical characteristics of the patients are reported in Table 1. Peripheral blood samples from all patients and controls have been collected and stored at -20°C until usage.

2.2. Clinical and Laboratory Data. Clinical and laboratory data were collected on a dedicated electronic support. Data related to a minor salivary gland biopsy (i.e., focus score (FS) or presence/absence of germinal centers (GCs)) were recorded. For each patient, the following information were recorded: sex, age at onset, age at diagnosis, presence of xerophthalmia, xerostomia, history of gland swelling, arthritis, and lymphoma. Patients' demographic and clinical findings are shown in Table 1.

Regarding the laboratory exams, the following parameters were evaluated: complete cell blood count, including the erythrocyte, leucocyte, and platelet counts; serum protein electrophoresis; serum levels of complements C3 and C4; antinuclear antibodies (ANA) and anti-SSA and anti-SSB antibodies; rheumatoid factor; and presence/absence of cryoglobulins. Each of these tests had to be positive in at least 2 occasions all along patients' clinical history to be considered positive. ANA were determined by means of indirect immunofluorescence (IIF) on Hep-2 and were considered present at a titer 1 : 160; anti-SSA and anti-SSB antibodies were determined by ELISA considering titers above the cut-off of the reference laboratory; the rheumatoid factor was determined by the Waaler-Rose test and/or Ra test; hypergammaglobulinemia and monoclonal component were determined by serum protein electrophoresis and, in case, serum and urine immunofixation; cryoglobulins were determined by cryoprecipitate detection (samples kept at 37°C, warm centrifugation, warm cell precipitation, serum conservation at 4°C,

TABLE 1: Clinical and laboratory data of the 195 SS patients.

Clinical features	
Sex (M/F)	9/186
Age (mean ± standard deviation, years)	58.1 ± 11.2
Age at diagnosis (mean ± standard deviation, years)	51.9 ± 11.1
Xerophthalmia	179/195 (91.7%)
Xerostomia	174/195 (89.2%)
Salivary gland swelling	44/195 (22.5%)
Arthritis	22/195 (11.2%)
Lymphoma	9/195 (4.6%)
Laboratory features	
ANA	168/195 (86.1%)
Anti-SSA	126/195 (64.6%)
Anti-SSB	86/195 (44.1%)
Hypergammaglobulinemia	67/195 (34.3%)
Rheumatoid factor	67/195 (34.3%)
Leukopenia	44/195 (22.5%)
Hypocomplementemia	21/195 (10.7%)
Monoclonal component	16/195 (8.2%)
Cryoglobulins	8/195 (4.1%)

ANA were considered positive if titer ≥ 1 : 160; anti-SSA, anti-SSB, and RF were considered positive according to the cut-off of the reference laboratory; hypergammaglobulinemia was diagnosed if total Ig ≥ 20% of total proteins; leukopenia was diagnosed if WBC < 4000/mm^3; hypocomplementemia was diagnosed if C3 < 80 mg/dl and/or C4 < 15 mg/dl.

and cryoprecipitate detection after 7 days). Patient laboratory findings are shown in Table 1.

2.3. DNA Extraction and Genotyping. Genomic DNA was isolated from peripheral blood mononuclear cells using a Qiagen blood DNA mini kit. We chose to analyze polymorphisms in four genes involved in immune response and inflammation that were previously associated with a higher risk to develop SLE. The selected SNPs were the following: rs7574865 (*STAT4*, chromosome 2), rs3099844 (*HCP5*, chromosome 6), rs33980500 (*TRAF3IP2*, chromosome 6), and rs1800872 and rs3024505 (*IL10*, chromosome 1). Genotyping was performed by allelic discrimination assays by TaqMan technology (Applied Biosystems, Foster City, CA, USA) and real-time PCR. Each assay was run with positive (samples previously confirmed by direct sequencing as heterozygous and/or variant homozygous) and negative controls.

2.4. Statistical Analysis. The Hardy–Weinberg equilibrium was verified for all SNPs by Pearson's χ^2 test. Differences in alleles and genotype frequencies between cases and controls were evaluated by Pearson's χ^2 test. Odds ratios (ORs) with 95% CI were calculated. The cut-off for statistical significance was $P < 0.05$. A genotype-phenotype correlation analysis has been performed comparing cases with and without specific manifestations and considering the heterozygotes and variant homozygotes together (1 degree of freedom (df)). All statistical analyses were performed by the SPSS program ver. 19 (IBM Corp., Armonk, NY, USA).

2.5. Haplotype Analysis. Haplotypes were inferred using Arlequin, version 3.5 [28]. Differences in the haplotype distribution between cases and controls were evaluated by χ^2 test.

3. Results

Clinical and laboratory data are presented in Table 1 and are in line with previous cohorts [29]. As expected, the presence of lymphoproliferative complications was quite rare with evidence of non-Hodgkin lymphoma (NHL) only in nine cases (4.6%). Specifically, 7/9 cases presented with the typical MALT in the major salivary glands while the other two experienced a nodal and splenic NHL localization, respectively.

Polymorphisms in the *STAT4*, *HCP5*, *TRAF3IP2*, and *IL10* genes were analyzed in 195 patients with SS and 248 healthy controls. Deviations from the Hardy-Weinberg equilibrium were not observed for all studied polymorphisms. The distribution of genotype and allele frequencies and the comparisons between cases and controls are presented in Table 2. Polymorphisms in the *STAT4*, *HCP5*, and *IL10* genes are associated with SS susceptibility. Both the variant alleles of rs7574865 in the *STAT4* gene and rs3099844 in the *HCP5* gene were significantly more prevalent in patients than in controls, with an OR = 1.91 (95% CI 1.41-2.59) and $P = 3 \times 10^{-5}$ for *STAT4* and OR = 2.44 (95% CI 1.49-3.99) and $P = 3 \times 10^{-4}$ for *HCP5*, respectively.

We also observed an allele additive effect for *STAT4* SNP: indeed, patients carrying one variant allele had an OR = 1.35 ($P = 0.15$), while patients carrying two variant alleles had an OR = 6.79 ($P < 0.0001$). Regarding the *HCP5* SNP, it is interesting to note that the only two subjects with a homozygous variant genotype were present in the case group.

Concerning the *IL10* gene, the genotypic frequencies of both analyzed polymorphisms (rs3024505 and rs1800872) were significantly different between SS patients and controls: the variant allele of rs3024505 resulted to be a susceptibility allele (OR = 1.52), while the variant allele of rs1800872 seemed to confer a protective effect for the development of the disease (OR = 0.65).

We have inferred the haplotypes between the two *IL10* polymorphisms and between the rs3099844 and rs33980500 SNPs since the *HCP5* and *TRAF3IP2* genes are located on the same chromosome. However, the haplotype analysis did not improve the significance of the single locus association (see Supplementary Table S1).

Moreover, we counted the total number of risk alleles in each subject, considering as risk alleles the allelic variant of rs7574865 (*STAT4*), rs3024505 (*IL10*), and rs3099844 (*HCP5*) SNPs (we counted two risk alleles for homozygous variant genotypes). Then, we compared the risk allele number distribution between cases and controls (Figure 1). As expected, the class with no risk allele was significantly more prevalent in controls than in patients ($P = 0.002$, OR = 0.5). On the contrary, classes with 2 or more risk alleles are significantly more represented in cases than in controls ($P < 0.001$, OR = 3.23). In particular, subjects with at least three risk alleles have a higher probability to develop the disease

TABLE 2: Case-control association study.

STAT4 rs7574865		SS (N = 195)	Controls (N = 243)	P	OR (95% CI)
	GG	92	150		
Genotypes	GT*	78	87	**0.002**	1.81 (1.23-2.65)
	TT**	25	6		
Alleles	G	262	387	**0.00003**	1.91 (1.41-2.59)
	T	128	99		
HCP5 rs3099844		SS (N = 195)	Controls (N = 248)	P	OR (95% CI)
	CC	149	221		
Genotypes	CA	44	27	**0.0003**	2.53 (1.5-4.24)
	AA	2	0		
Alleles	C	342	469	**0.0003**	2.44 (1.49-3.99)
	A	48	27		
TRAF3IP2 rs33980500		SS (N = 195)	Controls (N = 218)	P	OR (95% CI)
	CC	167	183		
Genotypes	CT	28	34	0.63	0.88 (0.51-1.5)
	TT	0	1		
Alleles	C	362	400	0.57	0.86 (0.51-1.44)
	T	28	36		
IL10 rs1800872		SS (N = 194)	Controls (N = 278)	P	OR (95% CI)
	CC	117	130		
Genotypes	CA	66	124	**0.004**	0.58 (0.40.0.84)
	AA	11	24		
Alleles	C	300	384	**0.005**	0.65 (0.49-0.88)
	A	88	172		
IL10 rs3024505		SS (N = 194)	Controls (N = 270)	P	OR (95% CI)
	CC	137	209		
Genotypes	CT	48	58	0.1	1.43 (0.94-2.17)
	TT	9	3		
Alleles	C	322	476	**0.025**	1.52 (1.05-2.21)
	T	66	64		

*GT vs. GG: $P = 0.15$ and OR = 1.35; **TT vs. GG: $P < 0.0001$ and OR = 6.79; $P = p$ value evaluated by Pearson's χ^2 test; OR (95% CI) = odd ratios with 95% confidence interval.

(OR = 36, $P < 0.001$) and the class with 4 risk alleles is observed only in cases and never in the controls.

We further performed a genotype-phenotype correlation analysis to evaluate if these SNPs contribute to the modulation of clinical phenotypes (significant results are reported in Table 3; for a complete report of the evaluations, see Supplementary Table S2). Patients carrying the STAT4 rs7574865 variant allele have a higher risk to develop the monoclonal component and leukopenia ($P = 0.002$, OR = 7.6; $P = 0.048$, OR = 2.01, respectively), while patients carrying the variant allele of TRAF3IP2 rs33980500 were less predisposed to develop anti-SSB (OR = 0.4 and $P = 0.043$). Interestingly, the variant allele of HCP5 SNP is associated with a higher risk to develop anti-SSA (OR = 3.07, $P = 0.006$), anti-SSB (OR = 2.66, $P = 0.005$), rheumatoid factor (OR = 2.17, $P = 0.028$), hypergammaglobulinemia (OR = 2.54, $P = 0.007$), leukopenia (OR = 2.1, $P = 0.047$), and lymphoma (OR = 7.23, $P = 0.002$). This result is particularly important considering the severity of this clinical manifestation:

patients carrying the A allele have a significantly increased risk to develop lymphoma. Moreover, the variant of HCP5 also is associated to the severity of the salivary gland FS ($P = 0.03$ and OR = 12) (Table 4).

4. Discussion

In this study, we confirm the association of SS with the studied polymorphism of STAT4 and we show for the first time an association with a specific variant of the HCP5 gene. Moreover, we describe that two variants in the IL10 gene are associated with susceptibility to SS, with a risk (rs3024505) and a protective (rs1800872) effect, respectively. Both variants in the HCP5 and STAT4 genes were associated with a higher risk to develop a specific clinical phenotype. No association between TRAF3IP2 SNP and SS came out; on the contrary, it seems to confer a protection towards the production of anti-SSB antibodies. An interesting result of our work is the possibility to define, with only three SNPs, a genetic

Numbers of risk alleles	Controls	SS	Comparisons	P	OR (CI 95%)
0	78	52	0 vs other	0.002	0.5 (0.33-0.77)
1	74	71	1 vs 0	0.14	1.49 (0.89-2.32)
2	32	47	2 vs 0	0.006	2.20 (1.25-3.90)
3	1	20	≥2 vs 0	<0.001	3.23 (1.88-5.55)
4	0	4	≥3 vs 0	<0.001	36 (4.72-274.37)
Tot	185	194			

The risk alleles considered are the variant alleles of rs7574865, rs3099844 and rs3024505 SNPs. Significant comparisons are reported in bold.

Figure 1: Counting of risk alleles in cases and controls.

Table 3: Associations between disease phenotypes and studied polymorphisms.

Gene	Phenotype	P	OR (95% CI)
	Anti-SSA	**0.006**	3.07 (1.83-7.05)
	Anti-SSB	**0.005**	2.66 (1.32-5.36)
	Rheumatoid factor	**0.028**	2.17 (1.08-4.9)
HCP5 rs3099844	Hypergammaglobulinemia	**0.007**	2.54 (1.28-5.86)
	Leukopenia	**0.047**	2.1 (1-4.23)
	Lymphoma	**0.002**	7.23 (1.73-33.7)
	Monoclonal component	**0.002**	7.6 (1.68-34)
STAT4 rs7574865	Leukopenia	**0.048**	2.01 (1-4.07)
TRAF2IP2 rs33980500	Anti-SSB	**0.043**	0.4 (0.16-0.99)

Table 4: Association between HCP5 SNP and severity of the focus score.

	Focus score	
	<3	≥3
HCP5 rs3099844		
AA	20	10
AC+CC	1	6

$P = 0.03$; OR = 12 (95% CI = 1.27-113.7).

profile model showing that the risk to develop the disease increases considerably with the number of risk alleles. In particular, subjects with at least three risk alleles have up to 36 times higher probability to develop the disease and subjects with 4 risk alleles are only present in cases and never observed in controls.

Considering the known involvement of STAT4 in the "*IFN signature*," the observed association between rs7574865 polymorphism and SS is not surprising [30]. *STAT4* SNPs have been already described in other autoimmune conditions such as rheumatoid arthritis and SLE [31], and an association

between the *STAT4* rs7574865 and the susceptibility to SS has been reported too [15, 18–20, 32]. Several studies observed a correlation between the minor allele of rs7574865 and higher levels of STAT4 mRNA [33, 34] and with increased sensitivity to IFN-alpha signalling [35]. These data could explain how the minor allele of rs7574865 confers a higher risk of developing SS. However, this SNP is located on the third intron of the *STAT4* gene and the precise mechanism that leads to the higher expression of STAT4 remains unclear. As in SS, the IL-17 axis gives a great contribution to the development and maintenance of the local inflammatory process [36]; it is also relevant to remind the known implication of STAT4 in Th17 response [37, 38]. According to this background, the association that we found between a *STAT4* SNP and the aberrant production of autoantibodies, cryoglobulins, and monoclonal component could be more easily explained.

Our study also describes for the first time an association between SS and a specific polymorphism of *HCP5*. In our previous work, this variant was found associated with the susceptibility to SLE and a very strong association was

observed with the presence of anti-SSA antibodies [25]. This association between *HCP5* and anti-SSA antibodies also emerged in our SS cohort in which the rs3099844 variant allele appears to be associated with anti-SSB antibodies and RF as well. It is likely that *HCP5* confers a risk to a more aggressive inflammatory pattern characterized by a broader autoantibody production. Indeed, the salivary glands in patients with SS seem to represent the main inflammatory site in which the exposition of autoantigens takes place [39, 40]. Although the role of autoantibodies in the pathogenesis of SS is still controversial, their production mirrors the severity of the inflammatory process at the tissue level. Indeed, it is known that anti-SSA antibodies are linked with the presence of a more severe inflammatory process [40]. The presence of a FS > 1 is, in fact, strongly associated with anti-SSA and anti-SSB antibodies, and in general, the presence of these antibodies seems to provide a 9-fold higher risk to have a FS > 1 compared to seronegative patients [41]. Higher FS also correlates with the presence of GCs and systemic manifestations [40]; the association between GCs and lymphoma development is actually a matter of debate [42, 43]. Considering the severity of this complication, the identification of predictive genetic biomarkers is important for patient monitoring. Indeed, till now, very few studies have investigated the genetic involvement in lymphoma in SS, and only few associations have been identified, e.g., with the *MHTFR* [44], *BAFF* [45], and *TNFAIP3* [46] genes. In our study, the association, although very preliminary, of *HCP5* variant with lymphoma development is a promising result. Overall, the association between *HCP5* rs3099844 SNP and specific laboratory features (autoantibodies and leukopenia) as well as with the severity of the FS leads to hypothesize a role of this variant in a more aggressive pattern of disease. The SNP has been previously associated to other conditions such as Stevens-Johnson syndrome and toxic epidermal necrolysis [47] as well as sclerosing cholangitis [48] in which anti-SSA antibodies have been described in up to 11% of cases. Moreover, a genome-wide study identified an association between this variant and cardiac manifestation in neonatal lupus that is known to be associated with anti-SSA antibodies [49]. A different polymorphism (rs2395029) of *HCP5* was associated to psoriasis and psoriatic arthritis [50].

Considering the analyzed *IL10* SNPs, for one of them (rs3024505), we found an association with SS. On the contrary, a protective effect was observed for the other variant (rs1800872). IL-10 is a pleiotropic cytokine able to suppress Th1 cell response, to downregulate *MHC* class II antigens and costimulatory molecules on macrophages, and, given its ability to enhance B cell survival and proliferation, to induce the production of immunoglobulin and autoantibody [51]. The *IL10* gene is located on chromosome 1, and several polymorphisms have been identified [52] with possible consequences on its production [53]. The different outcomes that we observed between these two polymorphisms in SS might have possible implication in the regulation of IL-10 production. In particular, the rs1800872 is localized in the promoter region; the variant allele could have a protective role for the development of SS because it is associated with increased IL-10 production [54], which modulates

the inflammatory response. However, the role of IL-10 in SS is still not clear.

Since in murine models a deficiency of the Act1 protein is able to determine a SS phenotype [23], we also investigated the *TRAF3IP2* gene. However, no contribution of *TRAF3IP2* gene polymorphism emerged in our study.

Although our cohort of patients is well characterized and accurately diagnosed, the limit of this study is represented by the small sample size. In particular, patients displaying a particularly severe pattern of disease were quite rare with only few cases experiencing lymphoproliferative complications. However, our results appear promising and possibly useful in identifying patients more prone to develop an aggressive disease. These data should be considered preliminary ones and a replication study is strongly recommended.

5. Conclusion

We confirm the associations between SNPs in the *STAT4* and *IL10* genes and SS susceptibility and we provide a novel association with a specific polymorphism in the *HCP5* gene. We also show how the genotyping of only three SNPs may allow to define a genetic risk profile for SS development.

Moreover, we also confirm the association between *HCP5* and the production of anti-SSA antibodies, and we further observe an association with other SS autoantibodies and with the FS. Taken all together, these associations might suggest a more aggressive pattern of disease in patients presenting the analyzed *HCP5* polymorphism. Our findings deserve further confirmation in larger cohorts and in populations of other ethnicities.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Preliminary results of the current study were presented as a poster at the 2016 EULAR congress and published as an abstract in the "Annals of the Rheumatic Diseases," 2016, 75, S2: THU0277 "Evaluation of Polymorphisms of STAT4, TRAF31P2 and HCP5 in Sjögren Syndrome: Association with Disease Susceptibility and Clinical Aspects."

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors' Contributions

Carlo Perricone and Paola Borgiani equally contributed to this work.

Acknowledgments

di varianti di suscettibilità nella sindrome di Sjögren: analisi di correlazione genotipo fenotipo."

Supplementary Materials

Table S1: comparison of the haplotype distribution between SS patients and controls. Table S2: complete list of genotype/phenotype correlation analyses. (*Supplementary Materials*)

References

[1] S. Kivity, M. T. Arango, M. Ehrenfeld et al., "Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review," *Journal of Autoimmunity*, vol. 51, pp. 17–22, 2014.

[2] J. E. Gottenberg, N. Cagnard, C. Lucchesi et al., "Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 8, pp. 2770–2775, 2006.

[3] C. P. Mavragani and M. K. Crow, "Activation of the type I interferon pathway in primary Sjogren's syndrome," *Journal of Autoimmunity*, vol. 35, no. 3, pp. 225–231, 2010.

[4] C. P. Mavragani, I. Sagalovskiy, Q. Guo et al., "Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease," *Arthritis & Rheumatology*, vol. 68, no. 11, pp. 2686–2696, 2016.

[5] T. O. R. Hjelmervik, K. Petersen, I. Jonassen, R. Jonsson, and A. I. Bolstad, "Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects," *Arthritis & Rheumatism*, vol. 52, no. 5, pp. 1534–1544, 2005.

[6] E. S. Emamian, J. M. Leon, C. J. Lessard et al., "Peripheral blood gene expression profiling in Sjögren's syndrome," *Genes & Immunity*, vol. 10, no. 4, pp. 285–296, 2009.

[7] J. C. Hall, L. Casciola-Rosen, A. E. Berger et al., "Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 43, pp. 17609–17614, 2012.

[8] S. M. Brookes, S. B. A. Cohen, E. J. Price et al., "T cell clones from a Sjögren's syndrome salivary gland biopsy produce high levels of IL-10," *Clinical and Experimental Immunology*, vol. 103, no. 2, pp. 268–272, 1996.

[9] S. Perrier, A. F. Serre, J. J. Dubost et al., "Increased serum levels of interleukin 10 in Sjögren's syndrome; correlation with increased IgG1," *The Journal of Rheumatology*, vol. 27, no. 4, pp. 935–939, 2000.

[10] R. Bertorello, M. P. Cordone, P. Contini et al., "Increased levels of interleukin-10 in saliva of Sjögren's syndrome patients. Correlation with disease activity," *Clinical and Experimental Medicine*, vol. 4, no. 3, pp. 148–151, 2004.

[11] J. Font, M. García-Carrasco, M. Ramos-Casals et al., "The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome," *Rheumatology (Oxford, England)*, vol. 41, no. 9, pp. 1025–1030, 2002.

[12] P. Willeke, M. Gaubitz, H. Schotte, H. Becker, W. Domschke, and B. Schlüter, "The role of interleukin-10 promoter polymorphisms in primary Sjögren's syndrome," *Scandinavian Journal of Rheumatology*, vol. 37, no. 4, pp. 293–299, 2008.

[13] B. Qin, J. Wang, Y. Liang, Z. Yang, and R. Zhong, "The association between TNF-α, IL-10 gene polymorphisms and primary Sjögren's syndrome: a meta-analysis and systemic review," *PLoS One*, vol. 8, no. 5, article e63401, 2013.

[14] A. Nezos and C. P. Mavragani, "Contribution of genetic factors to Sjögren's syndrome and Sjögren's syndrome related lymphomagenesis," *Journal of Immunology Research*, vol. 2015, Article ID 754825, 12 pages, 2015.

[15] B. D. Korman, M. I. Alba, J. M. le et al., "Variant form of STAT4 is associated with primary Sjögren's syndrome," *Genes & Immunity*, vol. 9, no. 3, pp. 267–270, 2008.

[16] R. J. Palomino-Morales, L. M. Diaz-Gallo, T. Witte, J. M. Anaya, and J. Martín, "Influence of STAT4 polymorphism in primary Sjögren's syndrome," *The Journal of Rheumatology*, vol. 37, no. 5, pp. 1016–1019, 2010.

[17] N. Gestermann, A. Mekinian, E. Comets et al., "STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling," *Genes & Immunity*, vol. 11, no. 5, pp. 432–438, 2010.

[18] for UK Primary Sjögren's Syndrome Registry, C. J. Lessard, H. Li et al., "Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome," *Nature Genetics*, vol. 45, no. 11, pp. 1284–1292, 2013.

[19] Y. Li, K. Zhang, H. Chen et al., "A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23," *Nature Genetics*, vol. 45, no. 11, pp. 1361–1365, 2013.

[20] K. E. Taylor, Q. Wong, D. M. Levine et al., "Genome-wide association analysis reveals genetic heterogeneity of Sjögren's syndrome according to ancestry," *Arthritis & Rheumatology*, vol. 69, no. 6, pp. 1294–1305, 2017.

[21] X. Li, "Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling," *Cytokine*, vol. 41, no. 2, pp. 105–113, 2008.

[22] F. Deng, J. Chen, J. Zheng et al., "Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome," *International Journal of Rheumatic Diseases*, vol. 19, no. 7, pp. 715–720, 2016.

[23] Y. Qian, N. Giltiay, J. Xiao et al., "Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome," *European Journal of Immunology*, vol. 38, no. 8, pp. 2219–2228, 2008.

[24] C. Perricone, C. Ciccacci, F. Ceccarelli et al., "TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development," *Immunogenetics*, vol. 65, no. 10, pp. 703–709, 2013.

[25] C. Ciccacci, C. Perricone, F. Ceccarelli et al., "A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene," *PLoS One*, vol. 9, no. 11, article e111991, 2014.

[26] C. Ciccacci, C. Perricone, C. Politi et al., "A polymorphism upstream MIR1279 gene is associated with pericarditis development in systemic lupus erythematosus and contributes to definition of a genetic risk profile for this complication," *Lupus*, vol. 26, no. 8, pp. 841–848, 2017.

[27] C. H. Shiboski, S. C. Shiboski, R. Seror et al., "2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three

international patient cohorts," *Annals of the Rheumatic Diseases*, vol. 76, no. 1, pp. 9–16, 2016.

[28] L. Excoffier and H. E. L. Lischer, "Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows," *Molecular Ecology Resources*, vol. 10, no. 3, pp. 564–567, 2010.

[29] C. Baldini, P. Pepe, L. Quartuccio et al., "Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients," *Rheumatology*, vol. 53, no. 5, pp. 839–844, 2014.

[30] G. Nordmark, M. L. Eloranta, and L. Ronnblom, "Primary Sjögren's syndrome and the type I interferon system," *Current Pharmaceutical Biotechnology*, vol. 13, no. 10, pp. 2054–2062, 2012.

[31] E. F. Remmers, R. M. Plenge, A. T. Lee et al., "STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus," *The New England Journal of Medicine*, vol. 357, no. 10, pp. 977–986, 2007.

[32] G. Nordmark, G. Kristjansdottir, E. Theander et al., "Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome," *Genes & Immunity*, vol. 10, no. 1, pp. 68–76, 2009.

[33] A. K. Abelson, A. M. Delgado-Vega, S. V. Kozyrev et al., "STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk," *Annals of the Rheumatic Diseases*, vol. 68, no. 11, pp. 1746–1753, 2009.

[34] A. Lamana, M. López-Santalla, R. Castillo-González et al., "The minor allele of rs7574865 in the STAT4 gene is associated with increased mRNA and protein expression," *PLoS One*, vol. 10, no. 11, article e0142683, 2015.

[35] S. N. Kariuki, K. A. Kirou, E. J. MacDermott, L. Barillas-Arias, M. K. Crow, and T. B. Niewold, "Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo," *The Journal of Immunology*, vol. 182, no. 1, pp. 34–38, 2009.

[36] L. W. Zhang, P. R. Zhou, P. Wei, X. Cong, L. L. Wu, and H. Hua, "Expression of interleukin-17 in primary Sjögren's syndrome and the correlation with disease severity: a systematic review and meta-analysis," *Scandinavian Journal of Immunology*, vol. 87, no. 4, article e12649, 2018.

[37] L. Guo, G. Wei, J. Zhu et al., "IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 32, pp. 13463–13468, 2009.

[38] L. Ronnblom, M.-L. Eloranta, and G. V. Alm, "The type I interferon system in systemic lupus erythematosus," *Arthritis & Rheumatism*, vol. 54, no. 2, pp. 408–420, 2006.

[39] E. A. Stea, J. G. Routsias, M. Samiotaki et al., "Analysis of parotid glands of primary Sjögren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets," *Clinical & Experimental Immunology*, vol. 147, no. 1, pp. 81–89, 2007.

[40] E. K. Kapsogeorgou, R. F. Abu-Helu, H. M. Moutsopoulos, and M. N. Manoussakis, "Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins," *Arthritis & Rheumatism*, vol. 52, no. 5, pp. 1517–1521, 2005.

[41] T. E. Daniels, D. Cox, C. H. Shiboski et al., "Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants," *Arthritis & Rheumatism*, vol. 63, no. 7, pp. 2021–2030, 2011.

[42] E. Theander, L. Vasaitis, E. Baecklund et al., "Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome," *Annals of the Rheumatic Diseases*, vol. 70, no. 8, pp. 1363–1368, 2011.

[43] E. A. Haacke, B. van der Vegt, A. Vissink, F. K. L. Spijkervet, H. Bootsma, and F. G. M. Kroese, "Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development," *Annals of the Rheumatic Diseases*, vol. 76, no. 10, pp. 1781–1784, 2017.

[44] S. Fragkioudaki, A. Nezos, V. L. Souliotis et al., "MTHFR gene variants and non-MALT lymphoma development in primary Sjögren's syndrome," *Scientific Reports*, vol. 7, no. 1, p. 7354, 2017.

[45] A. Nezos, A. Papageorgiou, G. Fragoulis et al., "B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome," *Journal of Autoimmunity*, vol. 51, pp. 89–98, 2014.

[46] G. Nocturne, J. Tarn, S. Boudaoud et al., "Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma," *Annals of the Rheumatic Diseases*, vol. 75, no. 4, pp. 780–783, 2016.

[47] P. Borgiani, D. di Fusco, F. Erba et al., "HCP5 genetic variant (rs3099844) contributes to nevirapine-induced Stevens Johnsons syndrome/toxic epidermal necrolysis susceptibility in a population from Mozambique," *European Journal of Clinical Pharmacology*, vol. 70, no. 3, pp. 275–278, 2014.

[48] T. H. Karlsen, A. Franke, E. Melum et al., "Genome-wide association analysis in primary sclerosing cholangitis," *Gastroenterology*, vol. 138, no. 3, pp. 1102–1111, 2010.

[49] R. M. Clancy, M. C. Marion, K. M. Kaufman et al., "Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus," *Arthritis & Rheumatism*, vol. 62, no. 11, pp. 3415–3424, 2010.

[50] Y. Liu, C. Helms, W. Liao et al., "A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci," *PLoS Genetics*, vol. 4, no. 4, article e1000041, 2008.

[51] L. Llorente, Y. Richaud-Patin, R. Fior et al., "In vivo production of interleukin-10 by non–T cells in rheumatoid arthritis, Sjöugren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity.," *Arthritis & Rheumatism*, vol. 37, no. 11, pp. 1647–1655, 1994.

[52] J. M. Kim, C. I. Brannan, N. G. Copeland, N. A. Jenkins, T. A. Khan, and K. W. Moore, "Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes," *The Journal of Immunology*, vol. 148, no. 11, pp. 3618–3623, 1992.

[53] J. Eskdale, G. Gallagher, C. L. Verweij, V. Keijsers, R. G. J. Westendorp, and T. W. J. Huizinga, "Interleukin 10 secretion in relation to human IL-10 locus haplotypes," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 16, pp. 9465–9470, 1998.

[54] K. Torres-Poveda, A. I. Burguete-García, M. Cruz et al., "The SNP at -592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development," *Infectious Agents and Cancer*, vol. 7, no. 1, p. 32, 2012.